<DOC>
	<DOCNO>NCT01862380</DOCNO>
	<brief_summary>The risk adrenal insufficiency patient nonclassical congenital adrenal hyperplasia due 21-hydroxylase deficiency well document . Indication cortisol replacement therapy situation acute stress long term thus controversial . The mineralocorticoid reserve patient never evaluate . Hypothesis : The glucocorticoid mineralocorticoid function adrenal gland woman nonclassical 21-hydroxylase deficiency comparable adrenal function healthy age- sexe- BMI-matched subject .</brief_summary>
	<brief_title>Adrenocortical Functions Women With Nonclassical 21-hydroxylase Deficiency .</brief_title>
	<detailed_description>The primary end-point study evaluate glucocorticoid function adrenal gland woman nonclassical 21-hydroxylase deficiency ( = patient ) compare maximal cortisol concentration obtain insulin tolerance test ( ITT ) patient healthy volunteer . The secondary end-point study determine % patient maximal plasma cortisol concentration great equal 18μg/dL ITT ; compare maximal plasma ACTH salivary cortisol concentration ITT two study group ; evaluate mineralocorticoid function patient compare variation ( change baseline ) plasma renin , aldosterone , urinary aldosterone , systolic diastolic blood pressure pulse wave velocity response sodium depletion patient healthy volunteer . Women nonclassical 21-hydroxylase deficiency follow Endocrinology reproduction illness Service BICETRE Hospital , LE KREMLIN-BICETRE , France female healthy volunteer propose participate . Before inclusion patient must genotyped patient healthy volunteer must undergo ACTH ( Synacthen 250 μg IV ) test plasma cortisol 17-hydroxyprogesterone concentration assessment . After inclusion : - ITT : IV injection 0.10-0.2U/kg insulin ( ACTRAPID ) 09h00 , dose adapt BMI , repeat measure 15 , 30 , 45 , 60 , 90 120 minute insulin injection assessment glucocorticoid function , One Day Hospital Endocrinology reproduction illness Service BICETRE Hospital , LE KREMLIN BICETRE . - Sodium depletion test : obtain PO administration 40 mg furosemide ( LASILIX ) 09h00 combination low sodium diet ( 20mmol Na/day ) repeat measure assessment mineralocorticoid function 24 hour drug administration Clinical Investigation Center The George POMPIDOU Hospital , Paris .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Groupe patient : woman age 1850 year nonclassical 21hydroxylase deficiency homozygous compound heterozygous mutation CYP21A2 plasma 17hydroxyprogesterone concentration stimulation synacthen &gt; = 10ng/mL Groupe healthy volunteer : age match female healthy volunteer plasma 17hydroxyprogesterone concentration stimulation synacthen &lt; 2ng/mL treatment oral local glucocorticoid &lt; 1 year oral estroprogestative contraception &lt; 3 month spironolactone &lt; 3 month cyproterone acetate &lt; 3 month treatment modify activity renin angiotensine aldosterone system &lt; 2 week pregnancy lactation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Adrenocortical function</keyword>
	<keyword>Adrenal hyperplasia , Congenital</keyword>
	<keyword>21-hydroxylase</keyword>
	<keyword>deficiency</keyword>
	<keyword>cortisol</keyword>
	<keyword>replacement therapy</keyword>
	<keyword>Woman</keyword>
	<keyword>Healthy people</keyword>
</DOC>